ZyVersa Therapeutics, Inc.
ZVSA· OTC
ZVSAZyVersa Therapeutics, Inc.
Filed Nov 14, 2024 · 10-Q · 45 days after period end · 0001493152-24-045351
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Net Income | -$2.40M | -$2.90M | -$679.09K | -$174.00 |
| EPS Diluted | -$2.43 | -$30.18 | — | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ZyVersa Therapeutics, Inc. · CIK 1859007 · Engraved from SEC EDGAR
ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d after period end
